Metronidazole 1% gel

国: アルメニア

言語: 英語

ソース: Դեղերի և բժշկական տեխնոլոգիաների փորձագիտական կենտրոնի գործունեության Հայաստանի Հանրապետությունում

ダウンロード 製品の特徴 (SPC)
08-05-2014

有効成分:

metronidazole

から入手可能:

Arpimed LLC

INN(国際名):

metronidazole

投薬量:

10mg/g

医薬品形態:

gel

処方タイプ:

Prescription

製品の特徴

                                SUMMARY PRODUCT CHARACTERISTIC (SPC)
METRONIDAZOLE 1% GEL
BRAND NAME – Metronidazole
1% gel
INTERNATIONAL NON-PROPERTY NAME - Metronidazole
COMPOSITION
Each gram contents:
_ACTIVE INGREDIENTS_: metronidazole - 10 mg;
_NON ACTIVE INGREDIENTS_: propylene glycol, carbomer-940,
methylparaben, triethanolamine,
disodium EDTA, purified water.
CHEMICAL NAME AND CAS NUMBER
2-(2-Methyl-5-nitro-1_H_-imidazol-1-yl)ethanol; 443-48-1.
PHARMACOLOGICAL GROUP AND ATC CODE
Metronidazole is a 5-nitroimidazole derivative with antibacterial
activity.
ATC Code:
J01X
D01.
PHARMACOLOGICAL ACTION
Metronidazole is an antiprotozoal and antibacterial agent which is
active against a wide
range of pathogenic micro-organisms. The mechanisms of action of
metronidazole in
rosacea are unknown but available evidence suggests that the effects
may be antibacterial
and/or anti-inflammatory.
PHARMACOKINETICS
The systemic concentration of Metronidazole following the topical
administration of 1 g
Metronidazole gel to 10 patients with rosacea ranged from 25 ng/ml
(limit of detection), to
66 mg/ml with a mean Cmax of 40.6 ng/ml.
The corresponding mean Cmax following the oral administration of a
solution containing 30
mg of metronidazole was 850 ng/ml (equivalent to 212 ng/ml if dose
corrected. The mean
Tmax for the topical formulation was 6.0 hours compared to 0.97 hours
for the oral solution.
USES
Indicated in the treatment of inflammatory papules, pustules and
erythema of rosacea.
DOSAGE AND ADMINISTRATION
_FOR TOPICAL ADMINISTRATION ONLY. _
The average period of treatment is three to four months. The
recommended duration of
treatment should not be exceeded. However, if a clear benefit has been
demonstrated,
continued therapy for a further three to four months period may be
considered by the
prescribing physician depending on the severity of the condition. In
clinical studies, topical
metronidazole therapy for rosacea has been continued for up to 2
years. In the absence of a
clear clinical improvement, therapy should be stopped.
_ADULTS:_ Metronidazol
                                
                                完全なドキュメントを読む
                                
                            

他の言語のドキュメント

情報リーフレット 情報リーフレット ロシア語 08-05-2014

この製品に関連するアラートを検索

ドキュメントの履歴を表示する